Independent considerations

Retreat Risk Checklist

A practical set of questions for adults considering retreats where ibogaine or ayahuasca are offered. It is designed to support careful verification, not to promote treatment or use.

A retreat setting does not remove uncertainty, medical risk, legal constraints, or the need for informed consent.

Before relying on an organizer’s assurances, compare what is said with what can be documented. The broader ibogaine and ayahuasca comparison can help frame why preparation, setting, health history, and local law deserve separate attention.

This checklist is not medical or legal advice. It cannot determine whether participation is appropriate for any individual. Questions about personal health, medications, testing, or risk should be brought to a licensed healthcare provider; questions about local rules should be checked through reliable official sources.

Start with records, not reassurance.

Useful answers are specific, documented, and open to independent verification. General statements about safety, experience, or legality are not a substitute for clear procedures.

I

Facility and staff

Ask who is present on site, what responsibilities each person holds, which qualifications can be verified, and how medical decisions are made when a concern arises.

II

Screening and disclosure

Ask what information is required before attendance, who reviews it, and whether disclosed conditions, medications, ECG findings, or laboratory results can change an eligibility decision.

III

Emergency readiness

Ask what equipment, trained personnel, transport options, and transfer arrangements are available if a participant needs urgent assessment or a higher level of care.

Ask what is assessed before anyone arrives.

For ibogaine in particular, cardiac risk is a central consideration because ibogaine has been associated with changes in cardiac rhythm. The FDA’s drug safety communications illustrate why serious safety questions should be checked against reliable health information rather than marketing language.

Ask whether an ECG is required, whether laboratory testing is requested, when those assessments occur, and who is responsible for reviewing them. Ask how the organizer handles a complete medication disclosure, including prescribed medications, over-the-counter products, and substances that may affect risk. Do not stop, start, or change medication based on a retreat’s guidance without consulting a licensed prescriber.

“A screening process is only meaningful when its limits, reviewer, timing, and follow-up decisions are clear.”

Expect a plan for adverse events.

An organizer should be able to explain what happens when a participant needs immediate care, who coordinates it, and how transfer to an appropriate facility is arranged.

  • Ask what on-site emergency capabilities exist, including trained personnel, available equipment, observation procedures, and the process for escalating concerns.
  • Ask for a plain explanation of ambulance access, travel time, nearest emergency facilities, and any arrangements for transfer or accompanying a participant.
  • Expect informed consent to describe foreseeable risks, uncertainty, alternatives, emergency limitations, privacy practices, and the right to decline or stop participation.
  • Ask what post-session follow-up is offered, how concerns after departure are handled, and what the organizer does when ongoing clinical care is needed.
  • For cultural context, distinguish retreat claims from the varied Indigenous and religious traditions associated with ayahuasca; ayahuasca’s documented cultural history is not a credential for any particular organizer.

Legal status may vary by substance, preparation, jurisdiction, import rules, and context. An organizer’s interpretation is not a legal determination. For U.S. readers, the DEA’s overview of drug scheduling provides a starting point for understanding why controlled-substance rules require careful jurisdiction-specific review.

Ask organizers to explain sourcing, storage, and handling in plain language. Ask what they mean by a dosing protocol, how decisions are documented, and what safeguards are used when a person’s circumstances change. These questions are not instructions for self-administration; they are a way to identify whether an organizer can describe accountable procedures.

Country-specific offerings should still be checked independently. For example, information presented by an ibogaine treatment Utah site, a European ibogaine retreat resource, or an ibogaine retreat in Mexico listing should not replace review of the applicable law, facility practices, or licensed medical advice.

Use the checklist before travel or payment.

What medical screening items should be clarified?

Ask what screening is required, who reviews it, and what happens when disclosed health conditions, medications, ECG findings, or laboratory results raise concerns. A licensed healthcare provider can help interpret personal medical questions.

What should informed consent include?

Expect a clear discussion of foreseeable risks, uncertainty, alternatives, the limits of available evidence, emergency arrangements, and the ability to decline or stop participation.

Why should legal status be checked independently?

Legal status can vary by country, state, substance, preparation, and context. Organizers’ descriptions should not substitute for checking applicable law through reliable official sources. Our evidence and policy context may help identify the kinds of distinctions worth checking.

What if the organizer cannot answer these questions clearly?

Pause rather than fill gaps with assumptions. Consider discussing health questions with a licensed provider and review the safety comparison framework for a structured way to separate claims, uncertainty, and known concerns.

Keep questions open until answers are verifiable.

Independent verification, careful documentation, and licensed professional guidance matter more than urgency, testimonials, or broad promises of safety.

Crossroot’s approach to careful information